Tiger Brokers

BUZZ- bluebird bio soars on revised offer from Carlyle, SK Capital Partners

Reuters
May 14
BUZZ- bluebird bio soars on revised offer from Carlyle, SK Capital Partners

** Shares of gene therapy maker bluebird bio BLUE.O rise 50.5% to $4.98 premarket

** Bluebird bio says its board approved the revised merger deal with investment firms Carlyle CG.O and SK Capital Partners

** Under terms of the amended deal, bluebird stockholders can elect to get $5 per share in cash or the original offer of $3 per share in cash plus a contingent value right of $6.84 per share that is payable upon achievement of a net sales milestone

** New offer price of $5 represents a 51% premium to BLUE's last closing price

** "The amended offer price provides an alternative for stockholders who would prefer greater upfront cash consideration instead of the potential upside of the CVR", the cos say

** Up to last close, stock down 60.3% YTD

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10